Table 2

S. maltophilia antimicrobial combination testing results—percent synergy by fractional inhibitory concentration indexa

Second antimicrobialValue(s) for first antimicrobial or combination
AMKGENTOBCIPLVXATMCAZTZPMEMCOLTIMCHLMINDOXSXTRIF
AMK10.81251
GEN13.3319314
TOB2.525611111
CIP08.82665164
LVX00045.081993653512
ATM015.712314
CAZ153036.57815221
TZP14 (10.5)2.5411123
MEM0.01
COL1 ANT3110037.5101765
TIM02017 (19.4)11 (91.7)4 (40)11.534341
CHL0000100047.41020
MIN101 (2.9)11 (6.7)0 (0)01 (2.3)0 (0)92.4531
DOX058.81
SXT000 (0)01 (4.5)1 (4.3)26 (14.6)0 (0)2 (3.8)087.31
RIF004000.0
  • a Highlighted figures, percentages of susceptible isolates at drug MIC; figures to right of highlights, numbers of combinations tested; figures to left of highlights, numbers of synergistic combinations (percent synergy where combination tested ≥10 times); 1 ANT, 1 combination antagonistic; AMK, amikacin; GEN, gentamicin; TOB, tobramycin; CIP, ciprofloxacin; LVX, levofloxacin; ATM, aztreonam; CAZ, ceftazidime; TZP, piperacillin-tazobactam; MEM, meropenem; COL, colistin; TIM, ticarcillin/clavulanate; CHL, chloramphenicol; MIN, minocycline; DOX, doxycycline; SXT, co-trimoxazole; RIF, rifampin.